Meeting
2013 ASCO Annual Meeting
First-line pemetrexed plus cisplatin followed by maintenance pemetrexed versus carboplatin-paclitaxel plus bevacizumab followed by maintenance bevacizumab (ERACLE) in advanced nonsquamous NSCLC: A quality-of-life-oriented, multicenter randomized phase III trial of the GOIM (Gruppo Oncologico Italia Meridionale).
Authors
Domenico Galetta
National Cancer Research Center Giovanni Paolo II, Bari, Italy
Domenico Galetta , Salvatore Pisconti , Saverio Cinieri , Vittorio Gebbia , Alessandro Morabito , Nicolo Borsellino , Evaristo Maiello , Antonio Febbraro , Annamaria Catino , Pietro Rizzo , Michele Montrone , Giovanni Simone , Vito Lorusso , Daniele Rizzi , Giovanni L. Pappagallo , Giuseppe Colucci
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01303926
Citation
J Clin Oncol 31, 2013 (suppl; abstr 8071)
DOI
10.1200/jco.2013.31.15_suppl.8071
Abstract #
8071
Poster Bd #
36C
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Describing the value of the most common first line NSCLC regimens in a real world setting.
First Author: Lee N. Newcomer
Poster
2024 ASCO Annual Meeting
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
First Author: Helena Alexandra Yu
Poster
2023 ASCO Annual Meeting
A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.
First Author: Yuming Zhu
Poster
2023 ASCO Annual Meeting
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.
First Author: Martin Reck